<DOC>
	<DOCNO>NCT02674269</DOCNO>
	<brief_summary>The study investigate safety efficacy UroGen 's TC-3 Gel sustain release Botulinum Toxin A ( BTX ) urinary bladder patient idiopathic overactive bladder .</brief_summary>
	<brief_title>Safety Efficacy Study Intravesical Instillations BotuGelTM , Slow Release RTGel Based Botox® Formulations , Idiopathic OAB Patients With Urinary Incontinence ( `` INTIMO2 '' )</brief_title>
	<detailed_description>Overactive bladder ( OAB ) syndrome , define International Continence Society ( ICS ) , presence `` urinary urgency , usually accompany frequency nocturia , without urgency urinary incontinence , absence urinary tract infection ( UTI ) obvious pathology . '' This study evaluate new mode treatment , intravesical bladder instillation Botox® mixed TC-3 may bypass drawback current bladder injection treatment mode OAB patient . Additionally provide preliminary safety efficacy data may serve basis large study explore safety efficacy aspects new mode treatment . 50 patient randomized horse race fashion ~2:2:1 ratio . The patient screen 3 week prior treatment . The patient request stop OAB medication 7 day prior treatment visit . 20 patient receive one instillation 300U BotuGel ( 60ml ) , 20 patient receive one instillation 400U BotuGel ( 60ml ) 10 patient receive one instillation 60 ml RTGel-TC-3 Gel ( Placebo ) , patient follow safety efficacy endpoints 6 week post instillation .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Main Female patient 18 75 year old diagnose idiopathic OAB . Patient symptom OAB ≥ 3 month prior screen . Patient nonresponder pharmacologic therapy intolerable side effect compliant treatment . On screen threeday void diary Patient frequency least 8 micturition per 24 hour &amp; Total ≥3 urgency urinary incontinence ( UUI ) episodes . Patient willing able initiate self catheterization posttreatment , require . Patients PVR ≤100 ml . Patient single PVR &gt; 100 ml follow two consecutive PVR measurement &lt; 100 ml may include study ) . Main Patient currently use CIC indwell catheter manage urinary incontinence Patient clinically significant Bladder Outlet Obstruction ( BOO ) . Patient active urinary tract infection . OAB due know neurological reason . Patient 24hour total urine volume void great 3,000 ml measure screening visit . Predominance stress incontinence opinion investigator , determine patient history . Use anticholinergics medication therapy treat symptom OAB within 7 day screen . Patient prior botulinum toxin therapy serotype within 12 week indication . Patient prior use Botulinum toxin therapy serotype urological condition . Patient previous pelvic radiation therapy . Patient treat two UTIs within last 6 month use prophylactic antibiotic prevent chronic UTIs . ANY condition identify may cause overactive bladder symptom</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Overactive bladder</keyword>
	<keyword>Botox</keyword>
	<keyword>TC-3 Gel</keyword>
	<keyword>Intravesical</keyword>
	<keyword>UroGen Pharma</keyword>
	<keyword>Botulinum Toxin</keyword>
	<keyword>Urgency</keyword>
	<keyword>OAB</keyword>
	<keyword>Incontinence</keyword>
	<keyword>I-QOL</keyword>
	<keyword>KHQ</keyword>
	<keyword>TBS</keyword>
	<keyword>RTG</keyword>
</DOC>